Preliminary safety assessment of CIGB-210, an investigational peptide for HIV infection.

Autor: Ramírez-Suárez AC; Pharmaceutical Department, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Paneque-Guerrero T; Pharmaceutical Department, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Casillas-Casanova D; Pharmaceutical Department, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Cosme K; Preclinical Research Direction, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Bacardí D; Preclinical Research Direction, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Duarte CA; Pharmaceutical Department, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Ancízar J; Preclinical Research Direction, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Brown E; Preclinical Research Direction, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Castro J; Preclinical Research Direction, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Suárez-Alba J; Preclinical Research Direction, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Garay H; Chemical and Physical Department, 113016Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba., Pereira K; Pharmaceutical Department, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba., Fernández-Ortega C; Pharmaceutical Department, 113016Center for Genetic Engineering and Biotechnology, Habana, Cuba.

Publikováno v: Human & experimental toxicology [Hum Exp Toxicol] 2022 Jan-Dec; Vol. 41, pp. 9603271211073708.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates.

Autor: Morera Y; Cancer Immunotherapy Laboratory, Department of Pharmaceuticals, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Playa Cubanacábn, Havana 10600, Cuba. yanelys.morera@cigb.edu.cu, Bequet-Romero M, Ayala M, Pérez PP, Castro J, Sánchez J, Alba JS, Ancízar J, Cosme K, Gavilondo JV

Publikováno v: Vaccine [Vaccine] 2012 Jan 05; Vol. 30 (2), pp. 368-77. Date of Electronic Publication: 2011 Nov 07.

CIGB-247 vaccine breaks immunological tolerance to the vascular endothelial growth factor in mice, rats, rabbits and non-human primates, without disturbing physiologic angiogenic processes

Autor: Morera, Y., Monica Bequet, Ayala, M., Gavilondo, J. V., Castro, J., Puente, P., Ancízar, J., Suarez, J., Sanchez, J., Cosme, K., Bacardí, D., Acevedo, B. E.

Publikováno v: Scopus-Elsevier
Biotecnología Aplicada, Vol 29, Iss 2, Pp 118-121

CIGB-247 is a novel cancer therapeutic vaccine that uses a mutated form of human vascular endothelial growth factor (VEGF) as antigen in combination with the oil-free adjuvant VSSP (very small sized proteoliposomes of Neisseria meningitidis outer mem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2ebf5bde49985f4c224bd5db4ab91683
http://www.scopus.com/inward/record.url?eid=2-s2.0-84863824276&partnerID=MN8TOARS

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.